Panbela Therapeutics Statistics
Total Valuation
PBLA has a market cap or net worth of $2.04 million. The enterprise value is $4.66 million.
| Market Cap | 2.04M |
| Enterprise Value | 4.66M |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, after market close.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PBLA has 4.85 million shares outstanding. The number of shares has increased by 17,090,783.81% in one year.
| Shares Outstanding | 4.85M |
| Shares Change (YoY) | +17,090,783.81% |
| Shares Change (QoQ) | +162,690.09% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 0.16% |
| Float | 4.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25
| Current Ratio | 0.25 |
| Quick Ratio | 0.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -175.78% |
| Return on Capital (ROIC) | -6,915.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.96M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.69M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.87% in the last 52 weeks. The beta is 0.78, so PBLA's price volatility has been lower than the market average.
| Beta (1Y) | 0.78 |
| 52-Week Price Change | -99.87% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 16.21 |
| Relative Strength Index (RSI) | 28.20 |
| Average Volume (30 Days) | 715,234 |
Short Selling Information
The latest short interest is 106,974, so 2.20% of the outstanding shares have been sold short.
| Short Interest | 106,974 |
| Short Previous Month | 177,730 |
| Short % of Shares Out | 2.20% |
| Short % of Float | 2.20% |
| Short Ratio (days to cover) | 0.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | -25.63M |
| Operating Income | -33.47M |
| Pretax Income | -25.44M |
| Net Income | -20.75M |
| EBITDA | -33.03M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -$259.50 |
Balance Sheet
The company has $2.58 million in cash and $5.19 million in debt, giving a net cash position of -$2.62 million or -$0.54 per share.
| Cash & Cash Equivalents | 2.58M |
| Total Debt | 5.19M |
| Net Cash | -2.62M |
| Net Cash Per Share | -$0.54 |
| Equity / Book Value | -4.71M |
| Book Value Per Share | -0.97 |
| Working Capital | -9.26M |
Cash Flow
| Operating Cash Flow | -25.25M |
| Capital Expenditures | n/a |
| Free Cash Flow | -25.25M |
| FCF Per Share | -$0.11 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PBLA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17,090,783.81% |
| Shareholder Yield | -17,090,783.81% |
| Earnings Yield | -1,017.44% |
| FCF Yield | -1,238.28% |
Analyst Forecast
The average price target for PBLA is $15.00, which is 3,471.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 3,471.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 18, 2024. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jan 18, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |